Janssen Appeals $1.64 Billion Award in Off-Label Drug Marketing Fraud Action
- May 02, 2025
Janssen Products, LP is appealing a recent federal court order requiring the company to pay nearly $1.64 billion after a jury found its marketing practices for two HIV drugs resulted in the submission of false claims for reimbursement to federal health care programs.
ARTICLE TAGS
You must be logged in to access this content.